Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classificação em ações #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Preço da ação
$451.59
Valor de mercado
$114.70B
Variação (1 dia)
-2.36%
Variação (1 ano)
-11.89%
País
US
Negociar Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Número de ações em circulação para Vertex Pharmaceuticals Incorporated (VRTX)
Número de ações em circulação em December 2025: 253.90M
De acordo com os últimos relatórios financeiros e o preço das ações da Vertex Pharmaceuticals Incorporated, o número atual de ações em circulação é 253.90M. No final de December 2024, a empresa tinha 257.50M ações em circulação. O número de ações em circulação é geralmente afetado por desdobramentos de ações e recompra de ações.
Histórico de ações em circulação da Vertex Pharmaceuticals Incorporated (VRTX) de 2000 a 2026
Ações em circulação no final de cada ano
Ano Ações em circulação Alterar
2026 (TTM) 253.90M -0.70%
2025 255.70M -0.70%
2024 257.50M -0.08%
2023 257.70M 0.62%
2022 256.10M -0.62%
2021 257.70M -0.82%
2020 259.84M 1.21%
2019 256.73M 0.96%
2018 254.29M 2.18%
2017 248.86M 2.16%
2016 243.59M 1.14%
2015 240.84M 2.52%
2014 234.92M 4.49%
2013 224.83M 6.08%
2012 211.95M 3.44%
2011 204.89M 2.24%
2010 200.40M 15.67%
2009 173.26M 23.27%
2008 140.56M 8.97%
2007 128.99M 13.92%
2006 113.22M 26.87%
2005 89.24M 13.58%
2004 78.57M 2.03%
2003 77.00M 1.66%
2002 75.75M 1.73%
2001 74.46M 10.02%
2000 67.68M 0.00%
Ações em circulação de empresas semelhantes ou concorrentes
Empresa Ações em circulação Diferença País
4.45B 1,651.81%
DK
102.90M -59.47%
US
190.00M -25.17%
BE
483.58M 90.46%
AU
61.42M -75.81%
NL